Genzyme Completes US Fill/Finish Relocation From Allston Facility

December 8, 2010
Genzyme has completed the move of its U.S.-product fill/finish operations from its troubled Allston, Mass., plant as required under an FDA consent decree. Fill/finish activities for the Gaucher’s disease drug Cerezyme (imiglucerase), Pompe disease drug Myozyme (alglucosidase alfa), Fabry disease drug Fabrazyme (agalsidase beta) and thyroid drug Thyrogen (thyrotropin alfa) are now performed at Genzyme’s Waterford, Ireland, plant and at an external contract manufacturer, the company said. Fill/finish activities for products sold outside of the U.S. must be moved by Aug. 31.
Drug GMP Report